TY - JOUR
T1 - The fear of cancer recurrence and progression in patients with pancreatic cancer
AU - Pijnappel, Esther N.
AU - Dijksterhuis, Willemieke P. M.
AU - Sprangers, Mirjam A. G.
AU - Augustinus, Simone
AU - de Vos-Geelen, Judith
AU - de Hingh, Ignace H. J. T.
AU - Dutch Pancreatic Cancer Group
AU - Molenaar, Izaak Q.
AU - Busch, Olivier R.
AU - Besselink, Marc G.
AU - Wilmink, Johanna W.
AU - van Laarhoven, Hanneke W. M.
N1 - Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. Funding Information: JdVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier and has received institutional research funding from Servier. All outside the submitted work. IHJTdH has received research funding from Roche and RanD Biotech, paid to the institute. JWW has served as a consultant for Shire, Servier, and Celgene and reports grants from Servier, Halozyne, Novartis, Celgene, Astra Zeneca, Pfizer, Roche, and Amgen and Merck. HWMvL reports a consult/advisory role for BMS, Celgene, Lilly, Merck, Nordic, and Servier and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche, and Servier. The other authors declare that they have no conflicts of interest. Publisher Copyright: © 2022, The Author(s).
PY - 2022/6
Y1 - 2022/6
N2 - Purpose: It is plausible that patients with pancreatic cancer experience fear of tumor recurrence or progression (FOP). The aim of this study was to compare FOP in patients with pancreatic cancer treated with surgical resection, palliative systemic treatment, or best supportive care (BSC) and analyze the association between quality of life (QoL) and FOP and the effect of FOP on overall survival (OS). Methods: This study included patients diagnosed with pancreatic cancer between 2015 and 2018, who participated in the Dutch Pancreatic Cancer Project (PACAP). The association between QoL and WOPS was assessed with logistic regression analyses. OS was evaluated using Kaplan–Meier curves with the log-rank tests and multivariable Cox proportional hazard analyses adjusted for clinical covariates and QoL. Results: Of 315 included patients, 111 patients underwent surgical resection, 138 received palliative systemic treatment, and 66 received BSC. Patients who underwent surgical resection had significantly lower WOPS scores (i.e., less FOP) at initial diagnosis compared to patients who received palliative systemic treatment or BSC only (P < 0.001). Better QoL was independently associated with the probability of having a low FOP in the BSC (OR 0.95, 95% CI 0.91–0.98) but not in the surgical resection (OR 0.97, 95% CI 0.94–1.01) and palliative systemic treatment groups (OR 0.97, 95% CI 0.94–1.00). The baseline WOPS score was not independently associated with OS in any of the subgroups. Conclusion: Given the distress that FOP evokes, FOP should be explicitly addressed by health care providers when guiding pancreatic cancer patients through their treatment trajectory, especially those receiving palliative treatment or BSC.
AB - Purpose: It is plausible that patients with pancreatic cancer experience fear of tumor recurrence or progression (FOP). The aim of this study was to compare FOP in patients with pancreatic cancer treated with surgical resection, palliative systemic treatment, or best supportive care (BSC) and analyze the association between quality of life (QoL) and FOP and the effect of FOP on overall survival (OS). Methods: This study included patients diagnosed with pancreatic cancer between 2015 and 2018, who participated in the Dutch Pancreatic Cancer Project (PACAP). The association between QoL and WOPS was assessed with logistic regression analyses. OS was evaluated using Kaplan–Meier curves with the log-rank tests and multivariable Cox proportional hazard analyses adjusted for clinical covariates and QoL. Results: Of 315 included patients, 111 patients underwent surgical resection, 138 received palliative systemic treatment, and 66 received BSC. Patients who underwent surgical resection had significantly lower WOPS scores (i.e., less FOP) at initial diagnosis compared to patients who received palliative systemic treatment or BSC only (P < 0.001). Better QoL was independently associated with the probability of having a low FOP in the BSC (OR 0.95, 95% CI 0.91–0.98) but not in the surgical resection (OR 0.97, 95% CI 0.94–1.01) and palliative systemic treatment groups (OR 0.97, 95% CI 0.94–1.00). The baseline WOPS score was not independently associated with OS in any of the subgroups. Conclusion: Given the distress that FOP evokes, FOP should be explicitly addressed by health care providers when guiding pancreatic cancer patients through their treatment trajectory, especially those receiving palliative treatment or BSC.
KW - Fear of cancer progression
KW - Fear of cancer recurrence
KW - Pancreatic ductal adenocarcinoma
KW - Pancreatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85125105427&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00520-022-06887-w
DO - https://doi.org/10.1007/s00520-022-06887-w
M3 - Article
C2 - 35169873
SN - 0941-4355
VL - 30
SP - 4879
EP - 4887
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 6
ER -